CXCL12 and prostate cancer: Taken together, these studies suggest that targeting the CXCR4/CXCL12 pathway results in decreased prostate progenitor survival in vitro and in vivo in androgen refractory cancer cell lines and potentially could be of therapeutic value against advanced prostate cancers.